CA3181092A1 - Tryptamine prodrugs - Google Patents

Tryptamine prodrugs

Info

Publication number
CA3181092A1
CA3181092A1 CA3181092A CA3181092A CA3181092A1 CA 3181092 A1 CA3181092 A1 CA 3181092A1 CA 3181092 A CA3181092 A CA 3181092A CA 3181092 A CA3181092 A CA 3181092A CA 3181092 A1 CA3181092 A1 CA 3181092A1
Authority
CA
Canada
Prior art keywords
compound
linear
alkyl
branched
co2h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3181092A
Other languages
English (en)
French (fr)
Inventor
Nathan Bryson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reunion Neuroscience Canada Inc
Original Assignee
Reunion Neuroscience Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reunion Neuroscience Canada Inc filed Critical Reunion Neuroscience Canada Inc
Publication of CA3181092A1 publication Critical patent/CA3181092A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3181092A 2020-06-30 2021-06-30 Tryptamine prodrugs Pending CA3181092A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063045901P 2020-06-30 2020-06-30
US63/045,901 2020-06-30
US202063109095P 2020-11-03 2020-11-03
US63/109,095 2020-11-03
US17/364,047 US11292765B2 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs
US17/364,047 2021-06-30
PCT/CA2021/050907 WO2022000091A1 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs

Publications (1)

Publication Number Publication Date
CA3181092A1 true CA3181092A1 (en) 2022-01-06

Family

ID=79032374

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3181092A Pending CA3181092A1 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs

Country Status (10)

Country Link
US (4) US11292765B2 (https=)
EP (1) EP4172145A4 (https=)
JP (2) JP7702654B2 (https=)
KR (2) KR20250103811A (https=)
CN (3) CN115867533B (https=)
AU (1) AU2021302692A1 (https=)
CA (1) CA3181092A1 (https=)
IL (2) IL299506B2 (https=)
MX (1) MX2022016212A (https=)
WO (1) WO2022000091A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
MX2022009528A (es) 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
CN115867533B (zh) * 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
WO2022040802A1 (en) * 2020-08-26 2022-03-03 Magicmed Industries Inc. Glycosylated psilocybin derivatives and methods of using
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
EP4263504A4 (en) * 2020-12-18 2025-05-14 COMPASS Pathfinder Limited Modified indole alkaloids for therapeutic uses
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
BR112023025599A2 (pt) 2021-06-08 2024-02-20 Entheogenix Biosciences Inc Ativadores de dimetoxifenilalquilamina de receptores de serotonina.
CA3225133A1 (en) 2021-07-07 2023-01-12 Matthew Alexander James Duncton N,n-dimethyltryptamine and related psychedlics and uses thereof
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof
EP4429672A4 (en) 2021-11-12 2025-04-30 Terran Biosciences Inc. PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF
US12404238B2 (en) 2021-12-10 2025-09-02 Caamtech, Inc. Psilocybin derivatives
JP2024546138A (ja) * 2021-12-14 2024-12-17 レユニオン ニューロサイエンス，インコーポレイテッド トリプタミンプロドラッグ
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023133477A1 (en) * 2022-01-06 2023-07-13 Terran Biosciences, Inc. Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250186369A1 (en) * 2022-03-07 2025-06-12 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493542A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE
AU2022446955A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493544A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
WO2023201293A2 (en) * 2022-04-13 2023-10-19 Caamtech, Inc. Tryptamine derivatives
CN115521240B (zh) * 2022-06-01 2024-05-28 杭州奥泰生物技术股份有限公司 一种二甲基色胺半抗原和人工抗原及其制备方法与应用
EP4561527A2 (en) * 2022-07-27 2025-06-04 Reconnect Labs AG Highly soluble formulations of harmine
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
CN116283885B (zh) * 2022-12-01 2025-02-14 杭州奥泰生物技术股份有限公司 一种帕罗西汀半抗原和人工抗原及其制备方法与应用
JP2026501775A (ja) * 2023-01-05 2026-01-16 リユニオン・ニューロサイエンス、インコーポレイテッド トリプタミンプロドラッグの薬物動態の改善
WO2024178051A2 (en) * 2023-02-22 2024-08-29 Caamtech, Inc. Tryptamine derivatives
EP4704822A1 (en) 2023-05-01 2026-03-11 ATAI Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025099725A1 (en) * 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025238416A1 (en) * 2024-05-16 2025-11-20 Mindset Pharma Inc. Indole derivatives, uses and compositions thereof
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) * 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
NL243249A (https=) 1958-09-12
CH373381A (de) 1959-07-13 1963-11-30 Sandoz Ag Verfahren zur Herstellung neuer basischer Indol-Derivate
CH386422A (de) 1960-03-30 1965-01-15 Sandoz Ag Verfahren zur Herstellung neuer Ester der Indol-Reihe
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2147991A1 (en) * 1993-09-01 1995-03-09 Richard A. Glennon Tryptamine analogs with 5-ht1d selectivity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2005300045A1 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
EP4219498A1 (en) * 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
CN115867533B (zh) * 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
EP4263504A4 (en) * 2020-12-18 2025-05-14 COMPASS Pathfinder Limited Modified indole alkaloids for therapeutic uses

Also Published As

Publication number Publication date
JP7702654B2 (ja) 2025-07-04
US20210403425A1 (en) 2021-12-30
WO2022000091A1 (en) 2022-01-06
MX2022016212A (es) 2023-03-02
CN119285526A (zh) 2025-01-10
EP4172145A4 (en) 2024-08-21
CN115867533A (zh) 2023-03-28
JP2025143280A (ja) 2025-10-01
IL299506A (en) 2023-02-01
IL299506B1 (en) 2025-06-01
CN115867533B (zh) 2024-07-23
KR20250103811A (ko) 2025-07-07
IL299506B2 (en) 2025-10-01
EP4172145A1 (en) 2023-05-03
KR102829078B1 (ko) 2025-07-04
US20220177427A1 (en) 2022-06-09
US11292765B2 (en) 2022-04-05
AU2021302692A1 (en) 2023-01-19
IL320601A (en) 2025-07-01
US20250129023A1 (en) 2025-04-24
US20250382267A1 (en) 2025-12-18
KR20230028543A (ko) 2023-02-28
CN119285527A (zh) 2025-01-10
JP2023531311A (ja) 2023-07-21

Similar Documents

Publication Publication Date Title
US11292765B2 (en) Tryptamine prodrugs
US20250051278A1 (en) Tryptamine prodrugs
KR100703103B1 (ko) 성기능 장애 치료용 알파-2-델타 리간드
EA007008B1 (ru) Триамидзамещённые индолы, бензофураны и бензотиофены в качестве ингибиторов микросомального белка, переносящего триглицериды, (мтр) и/или ингибиторов секреции аполипопротеина в (аро в)
WO2005016326A2 (en) Analogs of thalidomide as potential angiogenesis inhibitors
WO2018133670A1 (zh) 丁苯酞-替米沙坦杂合物及其制备方法和用途
ES2575689T3 (es) Compuestos y métodos para el tratamiento del dolor y otras enfermedades
JPWO2005021486A1 (ja) エステル誘導体及びその医薬用途
EA013644B1 (ru) Фенилсодержащие n-ацильные производные аминов и аминокислот, способ их получения, фармацевтическая композиция и их применение
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
HK40114605A (zh) 色胺前药
HK40114252A (zh) 色胺前药
HK40091294A (zh) 色胺前药
HK40091294B (zh) 色胺前药
HK40114112A (zh) 色胺前药
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
WO2011058943A1 (ja) Ｍｃｈ ｒ１アンタゴニスト活性を有する化合物とｎｐｙ ｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物
WO1997024030A1 (en) Pyrrolidine derivatives
WO2005016331A1 (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221201

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240826

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250609

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250609

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20250821

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250821

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250821

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250821

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250827

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250908

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260310

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260310

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260324

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260324